Avastin (bevacizumab) / Roche - LARVOL DELTA

Lens culinaris-agglutinin-reactive fraction of alpha-fetoprotein is a prognostic biomarker in atezolizumab plus bevacizumab for hepatocellular carcinoma. (PubMed, Eur J Gastroenterol Hepatol) - "AFP-L3 is a useful biomarker for predicting the response and prognosis of patients with ATZ/BV for u-HCC. AFP-L3 should be measured together with AFP and DCP levels."

Biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • AFP

Promising Response to Pyrotinib in Non-Small-Cell Lung Cancer with the Rare HER2 R456C Mutation: A Case Report. (PubMed, Curr Cancer Drug Targets) - "To the best of our knowledge, this study represents the first reported case demonstrating the promising efficacy of pyrotinib in HER2-altered NSCLC harboring the ra-re exon 12 R456C mutation. Heterogeneous alterations in the HER2 extracellular segment, such as R456C, may be targetable and could confer survival benefits with HER2-targeted inhibitors."

IO biomarker • Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2 • PD-L1

Off-label drugs in laryngology- what should the doctor and the patient know about such therapies? A consensus statement of the European Laryngological Society. (PubMed, Eur Arch Otorhinolaryngol) - "A patient's precise, explicit consent for the procedures including off-label drugs administration is mandatory. The second prerequisite is defining a need for creating based on recommendations by national or international scientific societies."

Journal • Otorhinolaryngology

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1/2 | N=11 | Terminated | Sponsor: Massachusetts General Hospital | N=43 ➔ 11 | Unknown status ➔ Terminated; slow accrual

Enrollment change • Trial termination • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK

BEVACIZUMAB: SOCIAL COMPLEXITIES AND OFF-LICENCE USE (ESPID 2025) - No abstract available

Infectious Disease

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2031 ➔ Jan 2032 | Initiation date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2030 ➔ Jan 2031

Trial completion date • Trial initiation date • Trial primary completion date • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma

BETTER: Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (clinicaltrials.gov) - P1/2 | N=46 | Recruiting | Sponsor: Melanoma and Skin Cancer Trials Limited | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Melanoma • Oncology • Solid Tumor

OliGRAIL: First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. (clinicaltrials.gov) - P3 | N=124 | Recruiting | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting ➔ Recruiting | Trial primary completion date: Feb 2025 ➔ Feb 2030

Enrollment open • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Potential complications of bevacizumab: gallbladder perforation. (PubMed, BMJ Case Rep) - No abstract available

Journal

Optimizing Dosing Strategy Demonstrates Cost-Effectiveness Among Emerging Treatments for Refractory mCRC (Journal of Clinical Pathways) - "'In light of the emerging evidence and treatment options for refractory mCRC, we evaluated relative cost-effectiveness of ReDO, TAS-BEV, and fruquintinib in patients with mCRC from a US payer perspective,' explained Tanios Bekaii-Saab..."

Media quote

Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival Benefit. (PubMed, JCO Clin Cancer Inform) - "The BALAD score had good prognostic ability for predicting OS and PFS in patients with advanced uHCC who underwent systemic therapies and was associated with treatment response. Application of the BALAD score offers increased precision in the prediction of outcome both for individual patients and for specific subgroups of patients with HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • AFP

The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings? (PubMed, Cancer) - "These real-world results support clinical trial data suggesting the benefit of adding bevacizumab to 1L chemotherapy may be limited to patients with high-risk prognostic factors."

Journal • Real-world evidence • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: CytoDyn, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2025 ➔ May 2025

Enrollment open • Trial initiation date • Colorectal Cancer • Oncology • Solid Tumor

Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review. (PubMed, Cancer Treat Rev) - "Recently reported post hoc analyses from the PAOLA-1 trial of maintenance olaparib plus bevacizumab versus bevacizumab alone for patients with newly diagnosed AOC and homologous recombination deficiency-positive tumors suggested PFS and OS benefit was achieved in both lower-risk (with stage III disease who had undergone upfront surgery and had complete resection) and higher-risk (with stage III disease who had undergone upfront surgery and had residual disease or who had received neoadjuvant chemotherapy, or with stage IV disease) patients, prompting reassessment of the role of bevacizumab in lower-risk patients. This review examines the role of bevacizumab in the AOC treatment pathway by discussing its efficacy and safety in the first-line, maintenance and recurrent settings, and evaluates the clinical implications of bevacizumab use across risk groups and lines of therapy."

Journal • Review • Oncology • Ovarian Cancer • Solid Tumor • HRD

Thyrotoxicosis induced by immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma:a case report (PubMed, Nihon Shokakibyo Gakkai Zasshi) - "Following three cycles of transarterial chemoembolization (TACE) for recurrent HCC, combination therapy with atezolizumab and bevacizumab (Atezo+Beva) was initiated in February Y, 20XX. Comprehensive evaluation led to a diagnosis of congestive heart failure associated with thyrotoxicosis. According to the IMbrave150 study, thyroid dysfunction occurs in 13.4% of patients receiving Atezo+Beva therapy;however, cases classified as Common Terminology Criteria for Adverse Events Grade 3 or higher, requiring hospitalization, are extremely rare, with an incidence of only 0.3%."

Checkpoint inhibition • Journal • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Hepatocellular Cancer • Oncology • Pulmonary Disease • Solid Tumor

Budget Analysis of the Implementation of Biosimilars in a Large Private Health Insurance Company in Southern Brazil (ISPOR 2025) - "There are no changes on the reimbursement reference list during the analyzed period. A 2-year cost comparison of infliximab, Adalimumab, Etanercept, Rituximab, Trastuzumab and Bevacizumab biosimilars versus reference biologicals was performed. The use of biosimilars in Brazil has been expanded, but entry and acceptance by both prescribers and healthcare providers is still challenging. There is a potential to increase access, relevant cost reduction and financial sustainability for a medium-sized insurance company in Brazil."

Reimbursement • US reimbursement

Telisotuzumab adizutecan (ABBV-400; Temab-A) monotherapy vs trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer with increased c-Met protein expression: An open-label, randomized, phase 3 trial. (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT06614192 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Metastases • Monotherapy • P3 data • Colorectal Cancer • Oncology • Solid Tumor • MET

IMbrella B: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (clinicaltrials.gov) - P3 | N=1000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology

Systematic Literature Reviews (SLRs) Of Clinical Outcomes And Patient-Reported Outcomes Of Recommended Treatments For Patients With Platinum-Resistant Ovarian Cancer (PROC) (ISPOR 2025) - "This report focuses on non-CT regimens recommended by the National Comprehensive Cancer Network (NCCN). Among the 66 included RCTs, eight studies compared five recommended regimens against CT: mirvetuximab soravtansine (MIRV), bevacizumab (BEV) + CT, rucaparib, tamoxifen and olaparib. Compared with CT, only MIRV (in FRα high tumors) and BEV ± CT demonstrated both OS and HRQoL improvement in PROC patients, with mOS remaining short. There is a substantial unmet need for clinically efficacious and tolerable treatments for PROC."

Clinical • Clinical data • Patient reported outcomes • Platinum resistant • Dry Eye Disease • Gastrointestinal Disorder • Oncology • Ophthalmology • Ovarian Cancer • Solid Tumor • BRCA • FOLR1

Safety and Tolerability of Concurrent Lung Stereotactic Body Radiation Therapy (SBRT), Decitabine, and Venetoclax Prior to Hematopoietic Stem Cell Transplant (ATS 2025) - "Although high-grade toxicities of combining Stereotactic Body Radiation Therapy (SBRT) with certain pharmacologic agents such as bevacizumab exist, the toxigenic effects of combining radiation and hypomethylating agents are not well known, making the treatment decisions in this case difficult and potentially informative.Patient Presentation: A 67-year-old former smoker initially presented with myalgia, fever, chills and weight loss. This case illustrates the absence of unexpected adverse effects associated with concurrent AML chemotherapy and SBRT radiation, underscoring the safety of this approach despite concerns for potential toxicity. While the simultaneous diagnoses of AML and Lung Adenocarcinoma in this patient are rare, this case shows that combining these treatments can be safe and efficacious for patients. This case challenges the hesitancy that envelops administering concurrent radiation and AML chemotherapy and provides valuable insight to future cases of..."

Clinical • Bone Marrow Transplantation • Fatigue • Gastrointestinal Disorder • Lung Adenocarcinoma • Lung Cancer • Musculoskeletal Pain • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • Transplantation

Cost-Effectiveness Analysis of Mirvetuximab Soravtansine in FRa-Positive Platinum-Resistant Ovarian Cancer in Japan (ISPOR 2025) - "OBJECTIVES: Current treatments for platinum-resistant ovarian cancer primarily involve nonplatinum chemotherapy, such as weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan, administered either as a single agent or in combination with bevacizumab. At the current price, MIRV was not cost-effective compared to chemotherapy. However, there is a high possibility that this treatment will become an innovative treatment by reducing the cost."

Cost effectiveness • HEOR • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Targeting metastatic breast cancer with Actinium-225 FAP-directed radiopharmaceutical therapy: a retrospective analysis of safety, efficacy and survival (SNMMI 2025) - "Hydration was provided during and after each cycle; premedication (antiemetics and/or dexamethasone) was given in selected cases...Previous treatments included chemotherapy 100%; surgery of the primary tumor 89%; hormonal therapy 78%; loco-regional radiotherapy 56%; therapy with Denosumab, Bevacizumab and PARP inhibitors (33%, respectively); immune-checkpoint inhibitors 22%; Trastuzumab 22%; β-FRT 22%... Despite the limited sample size and retrospective nature of this study, α-FRT with 225Ac-3BP-3940 appears to be a well-tolerated and effective treatment for metastatic BCa with otherwise limited therapeutic options. Its favorable safety profile and encouraging survival outcomes (up to nearly two years) support its potential role in advanced BCa, warranting further investigation through larger, prospective clinical trials."

Metastases • Retrospective data • Breast Cancer • Hematological Disorders • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Palliative care • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • FAP • HER-2

A retrospective analysis of safety, efficacy and survival of metastatic colorectal cancer patients treated with Actinium-225 FAP-directed radiopharmaceutical therapy (SNMMI 2025) - "Premedication (antiemetics/dexamethasone) was administered as needed... We studied 7 males and 3 females (age range 40-75 years at the time of the first α-FRT), previously treated with chemotherapy 100%; surgery of the primary 80%; surgery of metastases 60% (mainly in the liver, 40%); immunotherapy with Bevacizumab 90%; radiotherapy of the primary or metastases 60%; immune-checkpoint inhibitors 30%; β-FRT 50%... Our retrospective analysis shows that α-FRT as monotherapy with 225Ac-3BP-3940 or in TANDEM with β-emitters is a safe treatment option for patients with metastatic progressive CRC, without significant acute adverse events or long-term nephrotoxicity and with manageable long-term hematological toxicity; hepatotoxicity G2/G3 was documented in two patients with hepatic metastases. Considering the palliative purpose of 225Ac-3BP-3940 FRT in a metastatic advanced setting, both therapy response and survival outcomes were overall encouraging. Larger, prospective..."

Metastases • Retrospective data • Anemia • Colorectal Cancer • Fatigue • Hematological Disorders • Hepatocellular Cancer • Hepatology • Leukopenia • Oncology • Pain • Solid Tumor • FAP

Immune exclusion driven by myeloid cells contributes to resistance to checkpoint inhibitor and anti-angiogenic therapy in NSCLC (IMMUNOLOGY 2025) - "In a phase II trial combining bevacizumab with atezolizumab in metastatic NSCLC patients (with a disease control rate of 87.5%) whose disease progressed after atezolizumab monotherapy, we analyzed blood biomarker changes collected at baseline, one week post-therapy, and at disease progression. Combination therapy reduced suppressive and exhausted immune cells. These findings underscore the role of myeloid cells and factors such as IL-6, TCTP, and VEGF-A in resistance to therapy.Keywords: Animals Human Rodent; Cells Monocytes/Macrophages Neutrophils; Molecules Cytokines"

Checkpoint inhibition • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BSG • CD8 • CXCL5 • IL18 • IL6 • PD-1 • PD-L2

Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer. (PubMed, Cancer Drug Resist) - "Clinically, our findings demonstrated that high baseline levels of MAGEA3 in CRC patients were strongly associated with worse progression-free survival (PFS) following bevacizumab treatment. Collectively, these findings position MAGEA3 as a promising predictive biomarker for bevacizumab resistance in CRC, offering a potential solution to the longstanding challenge of treatment stratification."

Biomarker • Journal • Colorectal Cancer • Oncology • Solid Tumor • MAGEA3